California State Teachers Retirement System Purchases 13,039 Shares of Merit Medical Systems, Inc. $MMSI

California State Teachers Retirement System raised its position in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI) by 23.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,505 shares of the medical instruments supplier’s stock after purchasing an additional 13,039 shares during the period. California State Teachers Retirement System’s holdings in Merit Medical Systems were worth $4,791,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC acquired a new stake in shares of Merit Medical Systems in the 4th quarter valued at approximately $25,000. Maseco LLP acquired a new position in Merit Medical Systems during the 4th quarter worth approximately $26,000. Torren Management LLC bought a new position in Merit Medical Systems in the 4th quarter valued at approximately $38,000. Covestor Ltd boosted its position in Merit Medical Systems by 252.6% in the fourth quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock valued at $41,000 after buying an additional 336 shares in the last quarter. Finally, Danske Bank A S bought a new stake in shares of Merit Medical Systems during the third quarter worth $42,000. 99.66% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Raymond James Financial reiterated an “outperform” rating and set a $100.00 price target on shares of Merit Medical Systems in a report on Friday, July 31st. Citigroup reaffirmed an “outperform” rating on shares of Merit Medical Systems in a report on Monday, April 20th. Piper Sandler increased their target price on Merit Medical Systems from $96.00 to $106.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Compass Point set a $107.00 price target on Merit Medical Systems in a report on Monday, April 20th. Finally, BTIG Research upped their price objective on Merit Medical Systems from $100.00 to $105.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, Merit Medical Systems has a consensus rating of “Moderate Buy” and an average target price of $100.30.

Merit Medical Systems Price Performance

Merit Medical Systems stock opened at $89.04 on Friday. The stock has a market capitalization of $5.32 billion, a price-to-earnings ratio of 36.79, a PEG ratio of 2.21 and a beta of 0.49. Merit Medical Systems, Inc. has a 52-week low of $59.74 and a 52-week high of $94.75. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.79 and a current ratio of 4.20. The stock’s 50 day moving average price is $72.21 and its two-hundred day moving average price is $71.97.

Merit Medical Systems (NASDAQ:MMSI) last issued its earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.23. The business had revenue of $418.84 million for the quarter, compared to analyst estimates of $405.25 million. Merit Medical Systems had a net margin of 9.22% and a return on equity of 13.75%. Merit Medical Systems’s revenue was up 9.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.01 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. On average, equities analysts predict that Merit Medical Systems, Inc. will post 3.81 earnings per share for the current year.

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.